



3

ATTORNEY'S DOCKET NO: C1041/7016 (AWS)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lipford et al.
Serial No: 09/954,987
Filed: September 17, 2001
For: PROCESS FOR HIGH THROUGHPUT SCREENING OF CPG-BASED IMMUNO-AGONIST/ANTAGONIST
Examiner: unknown
Art Unit: 1645

RECEIVED
JAN 10 2002
TECH CENTER 1645-2300

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 18th day of December, 2001.


Yvonne Lingo

Commissioner for Patents
Washington, D.C. 20231

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby also makes the following additional information of record in the above-identified application.

The applicant would like to bring to the Examiner's attention the following co-pending non-provisional applications (copies enclosed) that may contain subject matter related to this application:

| <u>Docket No.</u> | <u>Serial No.</u> | <u>Filing Date</u> | <u>Inventor(s)</u> |
|-------------------|-------------------|--------------------|--------------------|
| C1037/7016 | 09/009,634 | 01-20-1998 | Hutcherson et al. |
| C1039/7009 | 09/082,649 | 05-20-1998 | Davis et al. |
| C1040/7004 | 09/146,072 | 09-02-1998 | Davis et al. |
| C1039/7017 | 09/191,170 | 11-13-1998 | Krieg et al. |
| C1041/7002 | 09/241,653 | 02-02-1999 | Wagner et al. |
| C1039/7027 | 09/306,281 | 05-06-1999 | Gramzinski et al. |
| C1040/7006 | 09/316,199 | 05-21-1999 | McCluskie et al. |
| C1039/7025 | 09/325,193 | 06-03-1999 | Davis et al. |
| C1039/7020 | 09/337,584 | 06-21-1999 | Krieg et al. |
| C1039/7021 | 09/337,619 | 06-21-1999 | Krieg et al. |
| C1039/7023 | 09/337,636 | 06-21-1999 | Krieg |
| C1039/7022 | 09/337,893 | 06-21-1999 | Krieg |
| C1041/7005 | 09/355,254 | 02-22-2000 | Wagner et al. |
| C1039/7028 | 09/361,575 | 07-27-1999 | Krieg |
| C1039/7029 | 09/415,142 | 10-09-1999 | Krieg et al. |
| C1039/7036 | 09/559,140 | 04-27-2000 | Noll et al. |
| C1039/7043 | 09/629,477 | 07-31-2000 | Krieg et al. |
| C1039/7042 | 09/630,319 | 07-31-2000 | Krieg et al. |
| C1039/7041 | 09/655,319 | 09-05-2000 | Krieg et al. |
| C1039/7035 | 09/669,187 | 09-25-2000 | Krieg et al. |
| C1039/7044 | 09/672,126 | 09-27-2000 | Hartmann et al. |
| C1040/7010 | 09/768,012 | 01-22-2001 | Davis et al. |
| C1037/7013 | 09/776,479 | 02-02-2001 | Bratzler et al. |
| C1041/7010 | 09/786,436 | 03-02-2001 | Wagner et al. |
| C1037/7017 | 09/800,266 | 03-05-2001 | Bratzler et al. |
| C1037/7018 | 09/801,839 | 03-08-2001 | Bratzler et al. |
| C1039/7048 | 09/818,918 | 03-27-2001 | Krieg et al. |
| C1039/7049 | 09/824,468 | 04-02-2001 | Krieg et al. |
| C1039/7052 | 09/888,326 | 06-22-2001 | Weiner et al. |
| C1041/7014 | 09/895,007 | 06-28-2001 | Schetter et al. |
| C1037/7019 | 09/920,313 | 08-01-2001 | Bratzler et al. |
| C1039/7053 | 09/931,583 | 08-16-2001 | Krieg et al. |
| C1037/7021 | 09/949,194 | 09-07-2001 | Petersen et al. |
| C1039/7057 | 09/965,101 | 09-26-2001 | Davis et al. |

Remarks

A copy of each of the above-identified items of information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Lipford et al., Applicant(s)

By: 

Alan W. Steele, Reg No. 45,128
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. C1041/7016 (AWS)
Dated: December 18, 2001